GGrantIndex
← Leaderboards

Jane Yu

Texas Tech University Health Scis Center

$8,820,051
Attributed
$12,119,589
Total exposure
8
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY201025
$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,119,589 · 8

By mechanism

R01$12,019,590 · 7
R56$99,999 · 1

Top collaborators

Most similar at Texas Tech University Health Scis Center

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsLungIn VitroIn VivoTsc2 GeneLymphangioleiomyomatosisMolecularPathway InteractionsMouse ModelWomanAffectSirolimusLeadNovel TherapeuticsPathogenesisFrap1 GenePre-ClinicalNew Therapeutic TargetMediatingMutationPharmaceutical PreparationsCell SurvivalMetastatic Neoplasm To The LungNeoplasm Metastasis

Grant awards (23)

Cellular determinants of responsiveness to mTOR inhibitors in LAM$739,236
R01 · FY2025 · HL
Dysregulation of sphingolipid metabolism and signaling in LAM$728,776
R01 · FY2025 · HL · contact PI
Investigate the role of extracellular vesicles in promoting the progression of pulmonary lymphangioleiomyomatosis$687,328
R01 · FY2025 · HL
Investigate the role of extracellular vesicles in promoting the progression of pulmonary lymphangioleiomyomatosis$679,938
R01 · FY2024 · HL
Uterine signaling networks in the pathogenesis of pulmonary lymphangioleiomyomatosis (LAM)$752,914
R01 · FY2023 · HL
Investigate the role of extracellular vesicles in promoting the progression of pulmonary lymphangioleiomyomatosis$699,460
R01 · FY2023 · HL
Polo-like kinase 1 and sphingosine-1-phosphate circuitry enhances TSC-mutant cell survival$99,999
R56 · FY2023 · DK · contact PI
Uterine signaling networks in the pathogenesis of pulmonary lymphangioleiomyomatosis (LAM)$761,338
R01 · FY2022 · HL
Investigate the role of extracellular vesicles in promoting the progression of pulmonary lymphangioleiomyomatosis$718,036
R01 · FY2022 · HL
Uterine signaling networks in the pathogenesis of pulmonary lymphangioleiomyomatosis (LAM)$770,161
R01 · FY2021 · HL
Uterine signaling networks in the pathogenesis of pulmonary lymphangioleiomyomatosis (LAM)$790,666
R01 · FY2020 · HL
Targeting prostaglandin biosynthesis and action in lymphangioleiomyomatosis$590,929
R01 · FY2019 · HL · contact PI
Targeting prostaglandin biosynthesis and action in lymphangioleiomyomatosis$601,109
R01 · FY2018 · HL · contact PI
Targeting prostaglandin biosynthesis and action in lymphangioleiomyomatosis$651,071
R01 · FY2017 · HL · contact PI
Prostaglandin biosynthesis: a novel therapeutic target in TSC disorders$237,000
R01 · FY2016 · DK · contact PI
Prostaglandin biosynthesis: a novel therapeutic target in TSC disorders$237,000
R01 · FY2015 · DK · contact PI
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM$377,239
R01 · FY2014 · HL · contact PI
Prostaglandin biosynthesis: a novel therapeutic target in TSC disorders$265,313
R01 · FY2014 · DK · contact PI
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM$40,481
R01 · FY2014 · HL · contact PI
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM$405,784
R01 · FY2013 · HL · contact PI
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM$426,245
R01 · FY2012 · HL · contact PI
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM$430,166
R01 · FY2011 · HL · contact PI
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM$429,400
R01 · FY2010 · HL · contact PI